News | FDA | April 29, 2024

Elekta Instrument AB recalls disposable biopsy needle kit for Leksell Stereotactic System for possibly containing microscopic stainless steel debris on the inside of the biopsy needle

Elekta Instrument AB recalls disposable biopsy needle kit for Leksell Stereotactic System for possibly containing microscopic stainless steel febris on the inside of the biopsy needle

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable Biopsy Needles (911933) from one batch (837838839) which can contain some microscopic stainless steel debris on the inside of the biopsy needle. The presence of debris in biopsy samples can hinder examination and delay the process. Moreover, there's a risk of debris being deposited in the brain, which could affect future MRI scans, potentially rendering them useless or unobtainable.

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

Recalled Product

  • Product Names: Disposable Biopsy Needles (911933)
  • Product Codes: HAW
  • Lot Number: 837838839
  • Distribution Dates: August 29, 2023 to January 5, 2024
  • Devices Recalled in the U.S.: 10
  • Date Initiated by Firm: March 15, 2024

Device Use

The Leksell Stereotactic System helps doctors locate and diagnose brain disorders. The Disposable Biopsy Needle Kit is used in neurosurgery for precise brain tissue sampling. It's designed for use with the Leksell Stereotactic System, allowing surgeons to obtain tissue samples accurately and minimally invasively.

Reason for Recall

Elekta Instrument AB is recalling Disposable Biopsy Needles (911933) from one batch (837838839) which can contain some microscopic stainless steel debris on the inside of the biopsy needle. The material in the debris is stainless steel, the same material as the biopsy needle.

If debris on the inside of the biopsy needle comes loose, it may appear in the biopsy sample and delay or make examination difficult. There is also a potential risk of debris being deposited in the brain. The long term functional consequences of such particles in the brain are unknown. If this occurs, the metallic debris could cause future MRI scans of the brain to be useless or even unable to be obtained. This is a serious negative consequence in a patient with a brain tumor who will require brain MRI surveillance scans for life, with no alternative available.

There have been no reported injuries and no reports of death associated with this issue.

Who May be Affected

  • Health care professionals, specifically specialists in brain disorders, who use the Disposable Biopsy Needle Kit and Leksell Stereotactic System
  • People receiving care using the Disposable Biopsy Needle Kit and Leksell Stereotactic System

What to Do

On March 15, 2024, Elekta sent all affected customers an Urgent Recall Notification.

The letter requested customers to:

  • Remove and dispose all Disposable Biopsy Needles (911933) from batch 837838839.
    • Contact the local Elekta representative for ordering replacement needle kits.
  • Post this notice in a place accessible to all users and advise appropriate personnel.
  • Complete the included Acknowledge Form and return it to Elekta.

Contact Information

Customers in the U.S. with questions about this recall should contact Elekta Instrument AB at (855) 693-5358.

Additional Resources

How do I report a problem?

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using an online form, regular mail, or FAX.


Related Content

News | Computed Tomography (CT)

April 17, 2025 — NANO-X IMAGING LTD has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ...

Time April 18, 2025
arrow
News | Breast Imaging

April 15, 2025 — CureMetrix, a provider of AI-driven medical imaging solutions, has announced that its AI-based cmAngio ...

Time April 17, 2025
arrow
News | Radiation Dose Management

April 7, 2025 — DOSIsoft, a provider of patient-specific imaging and dosimetry software solutions, recently announced ...

Time April 08, 2025
arrow
News | Prostate Cancer

March 28, 2025 — Novartis has announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu ...

Time March 31, 2025
arrow
News | Breast Imaging

March 20, 2025 — GE HealthCare has launched Invenia Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound ...

Time March 21, 2025
arrow
News | Computed Tomography (CT)

March 10, 2025 — Siemens Healthineers has received Food and Drug Administration clearance for its Naeotom Alpha class of ...

Time March 11, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

Prenuvo has announced FDA clearance for its AI-powered Prenuvo Body Composition report, marking a significant milestone ...

Time February 13, 2025
arrow
News | Prostate Cancer

Feb. 10, 2025 —Ibex Medical Analytics recently announced it has received U.S. Food and Drug Administration (FDA) 510(k) ...

Time February 10, 2025
arrow
News | SPECT Imaging

Feb. 5, 2025 — Serac Healthcare Ltd., a clinical radiopharmaceutical company developing an innovative molecular imaging ...

Time February 05, 2025
arrow
News | Artificial Intelligence

Feb. 4, 2025 — Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 ...

Time February 04, 2025
arrow
Subscribe Now